BioXcel Therapeutics Inc(BTAI) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -4.23 | Insider Own | 2.15% | Shs Outstand | 31.3M | Perf Week | - |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | 20.74% | Insider Trans | -5.57% | Shs Float | 30.6M | Perf Month | -91.07% |
| Enterprise Value | 0.09B | PEG | - | EPS next Q | - | Inst Own | 20.13% | Short Float | 20% | Perf Quarter | -93.84% |
| Income | -0.07B | P/S | 3.12 | EPS this Y | 52.88% | Inst Trans | -2.67% | Short Ratio | 1 | Perf Half Y | -95.38% |
| Sales | 0.00B | P/B | - | EPS next 5Y | - | ROA | -259.62% | Short Interest | 6.12M | Perf YTD | -95.38% |
| Book/sh | -3.69 | P/C | 0.17 | EPS past 3/5Y | 60.75% 37.62% | ROE | - | 52W High | -98.28% ($4.29) | Perf Year | -97.93% |
| Cash/sh | 0.44 | P/FCF | - | Sales past 3/5Y | 19.63% - | ROIC | - | 52W Low | 7.1% ($0.07) | Perf 3Y | -99.88% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 66.63% | Gross Margin | 22.78% | Volatility(W/M) | 35.2% 18.85% | Perf 5Y | -99.98% |
| Dividend TTM | - | EV/Sales | 125.62 | Sales Y/Y TTM | -14.52% | Oper. Margin | -5970.89% | ATR (14) | 0.1 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.21 | EPS Q/Q | 80.15% | Profit Margin | -9549.87% | RSI (14) | 20.14 | Recom | 4 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.21 | Sales Q/Q | 51.67% | SMA20 | -88.75% ($0.62) | Beta | 0.3 | Target Price | $1 |
| Payout | - | Debt/Eq | - | Earnings | 2026/5/15 | SMA50 | -91.2% ($0.8) | Rel Volume | 0 | Prev Close | $0.07 |
| Employees | 29 | LT Debt/Eq | - | EPS/Sales Surpr. | -1.41% -46% | SMA200 | -94.48% ($1.27) | Avg Volume(3M) | 6.11M | Price | $0.07 |
| IPO | 2018/3/8 | Option/Short | No/No | Trades | 0 | Volume | - | Change | - |
🧠 This is an AI-driven neuroscience drug development company that holds Igalmi (IGALMI), a treatment for acute agitation symptoms associated with schizophrenia and bipolar disorder. Formulated as a sublingual film for rapid absorption, the dexmedetomidine-based therapy has received FDA approval, and the company is working to expand its indications through broader at-home prescribing and treatment of agitation in Alzheimer's disease.
Over the past 1 year, on the lower side
98% below its 1-year high.
Traded less than usual. That is 0% of its average volume.
BTAI has weak earnings and a weak balance sheet
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +52.9% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $312. Peers typically go for $212.
Tap to view numbers
Not enough quarters to judge yet
Only 1 quarter(s) reported, so no grade yet.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Sell.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -100.0%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
20.0% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #83 of 84 in the industry
Based on market cap of $2M.
AKAN#79 Akanda Corp $3M PER - 
SXTC#80 China SXT Pharmaceuticals Inc $3M PER - 
PRFX#81 PRF Technologies Ltd $2M PER - 
SBFM#82 Sunshine Biopharma Inc $2M PER - BTAI#83 BioXcel Therapeutics Inc $2M PER - 
FAQ
What kind of company is BTAI?
BTAI belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of BTAI?
The market cap of BTAI is approximately $2M, ranking 5,829 within its sector.
What is the 52-week high and low for BTAI?
BTAI has recorded a 52-week high of $4.29 and a low of $0.07.
